The focus of the Clinical Malaria Group is the evaluation of the safety and efficacy of candidate antimalarials, using the induced blood stage malaria (IBSM) model in healthy human volunteers. Developed by the previous group lead Professor James McCarthy, the model has been used to evaluate 10 investigational medicinal products. Models have been established for an artemisinin-sensitive and an artemisinin-resistant P. falciparum strain, and other Plasmodium species including P. vivax and P. malariae. The model has also enabled the conduct of studies to evaluate transmission-blocking interventions, and has enabled the conduct of exploratory studies to evaluate immunological and pathophysiological response to infection.
CURRENT RESEARCH
- Clinical trials to evaluate candidate antimalarials
- Using the IBSM model to improve understanding of the pathogenesis of malaria
- Dr Rebecca Webster, Clinical Operations Manager
- Dr Fiona Amante, Laboratory Manager
- Helen Jennings, Quality Manager
- Dr Louise Marquart, Senior Statistician
- Melissa Fernandez, Clinical Trials Scientist
- Adam Potter, Medical Writer
- Azrin Abd-Rahman, Pharmacometrician
- Sam McEwan, Statistician
- Associate Professor Katharine Trenholme, Senior Research Fellow
- Jeremy Gower, Research Assistant
- Hayley Mitchell, Research Assistant
- Sean Lynch, Research Assistant
- Arya Sheela Nair, Research Assistant
- Jenny Peters, Scientific Officer
- Brighid O’Neill, Insectary Manager
- Juanita Heunis, Insectary Technician
- Isabelle Park, Clinical Trials Assistant
- Stephen Woolley, MD candidate
- Nick Cruikshank, Honours student
We gratefully acknowledge support from the following organisations and funding bodies
- The Medicines for Malaria Venture
- The Bill and Melinda Gates Foundation